Skip to Main Content

Author Details

Lohith Gowda
Yale Cancer Center and Yale School of Medicine
2018
34
10
Wade Schulz (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37903992Post-transplantation cyclophosphamide is associated with increased bacterial infections.Bone Marrow Transplant2024
36342852Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.Blood Adv2023
37961434Impact of Memory T Cells on SARS-COV-2 Vaccine Response in Hematopoietic Stem Cell Transplant.bioRxiv2023
36949156Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients.Leukemia2023
37312418Microfluidic Immuno-Serolomic Assay Reveals Systems Level Association with COVID-19 Pathology and Vaccine Protection.Small Methods2023
36606713Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia.Am J Hematol2023
36827681Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.Blood Adv2023
34551064Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.Blood Adv2022
36093346Microfluidic immuno-serology assay revealed a limited diversity of protection against COVID-19 in patients with altered immunity.bioRxiv2022
35013047Azacitidine maintenance in AML post induction and posttransplant.Curr Opin Hematol2022
35081472Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.Transplant Cell Ther2022
33482113Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study.Lancet Haematol2021
33864019Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.Bone Marrow Transplant2021
33836312Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults.Transplant Cell Ther2021
33929058Screening of blood donors for sickle cell trait using a DNA-based approach: Frequency in a multiethnic donor population.Transfusion2021
33551344Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.Clin Lymphoma Myeloma Leuk2021
34499090Life Expectancy After Allogeneic Stem Cell Transplant-In It for the Long Haul?JAMA Oncol2021
34551341Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.Transplant Cell Ther2021
34477024Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant.Leuk Lymphoma2021
34017072Correction to: Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation.Bone Marrow Transplant2021
34052505Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis.Transplant Cell Ther2021
33345654A case of acute myeloid leukemia with unusual germline <i>CEBPA</i> mutation: lessons learned about mutation detection, location, and penetrance.Leuk Lymphoma2021
32128834Investigation of increased platelet alloimmunization screening in the era of pathogen-reduced platelets treated with psoralen/UV light.Transfusion2020
32727701Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib.Clin Lymphoma Myeloma Leuk2020
32643494Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.Leuk Lymphoma2020
32362171Clinical outcomes and characteristics of patients with <i>TP53</i>-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience.Leuk Lymphoma2020
32338096Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought?Leuk Lymphoma2020
32182435<i>Cui bono?</i> Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes.Expert Rev Hematol2020
30446740Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.Bone Marrow Transplant2019
30537213A dual strategy to optimize hematopoietic progenitor cell collections: validation of a simple prediction algorithm and use of collect flow rates guided by mononuclear cell count.Transfusion2019
30683577HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.Curr Res Transl Med2019
30943051Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations.Leuk Lymphoma2019
30737868The impact of a multimodal approach to vancomycin discontinuation in hematopoietic stem cell transplant recipients (HSCT) with febrile neutropenia (FN).Transpl Infect Dis2019
29949188CAR-T cell manufacture: snatching victory when defeat is looming.Transfusion2018
  • 1 - 34 of 34

Recommended Authors

University Hospital Dresden
Career Start Year 2018
Number of shared co-authors 0
University of Pittsburgh
Career Start Year 2013
Number of shared co-authors 1
Memorial Sloan Kettering Cancer Center
Career Start Year 2013
Number of shared co-authors 2
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 0
The Ohio State University
Career Start Year 2008
Number of shared co-authors 3
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 0
MedStar Washington Hospital Center
Career Start Year 2006
Number of shared co-authors 1
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 2
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 2
University of Colorado Division of Hematology
Career Start Year 2004
Number of shared co-authors 3
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 2
College of Medicine, University of Florida
Career Start Year 2003
Number of shared co-authors 1
Oregon Health and Science University
Career Start Year 2003
Number of shared co-authors 0
Oregon Health Sciences University
Career Start Year 2002
Number of shared co-authors 0
Princess Margaret Cancer Centre
Career Start Year 2001
Number of shared co-authors 0
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 1
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 1
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 4
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 3
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 0
Washington University School of Medicine
Career Start Year 1990
Number of shared co-authors 1
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 1
University Hospitals of Cleveland
Career Start Year 1988
Number of shared co-authors 2
University of Colorado, Aurora CO.
Career Start Year 1987
Number of shared co-authors 1
University of Texas Southwestern Medical Center
Career Start Year 1987
Number of shared co-authors 3
Cancer and Blood Disease Institute, Children's Hospital Los Angeles
Career Start Year 1986
Number of shared co-authors 0
Sidney Kimmel Cancer Center, Johns Hopkins University
Career Start Year 1986
Number of shared co-authors 2
Oregon Health & Science University
Career Start Year 1983
Number of shared co-authors 3
University of Leipzig
Career Start Year 1982
Number of shared co-authors 1
Washington University School of Medicine
Career Start Year 1978
Number of shared co-authors 2

Collaborators

Memorial Sloan-Kettering Cancer Center
Co-authored papers 4
Yale School of Medicine
Co-authored papers 4
Smilow Cancer Center, Yale University School of Medicine
Co-authored papers 4
Duke University Medical Center
Co-authored papers 4
Yale Cancer Center and Smilow Cancer Hospital, Yale University School of Medicine
Co-authored papers 3
Yale University
Co-authored papers 3
The Ohio State University Wexner Medical Center
Co-authored papers 2
Yale University
Co-authored papers 2
Institute of Medicine, University of Tsukuba
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Co-authored papers 2
and Blood Institute, National Institutes of Health
Co-authored papers 2
Co-authored papers 2
Yale School of Medicine, Yale School of Public Health
Co-authored papers 2
Yale University
Co-authored papers 2
Yale School of Medicine
Co-authored papers 2
Yale University School of Medicine
Co-authored papers 2
Yale University School of Medicine
Co-authored papers 1
Yale School of Medicine
Co-authored papers 1
Yale University
Co-authored papers 1
Marcus Center for Cellular Cures, Duke University
Co-authored papers 1
The University of Texas MD Anderson Cancer Center
Co-authored papers 1
Yale University
Co-authored papers 1
Yale University
Co-authored papers 1
Center for Transfusion and Cellular Therapy, Emory University School of Medicine
Co-authored papers 1
Institute of Pathogens and Vectors, Dali University
Co-authored papers 1
Yale University
Co-authored papers 1
Yale University School of Medicine, Yale-New Haven Hospital
Co-authored papers 1
Clinical Services
Co-authored papers 1
Yale University School of Medicine
Co-authored papers 1